In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and mortality compared with pioglitazone

Q: What is the clinical evidence from this study?

Population: Alzheimer's disease (in vitro model) (n=150). Intervention: Ginsenoside Rg1 vs. Aβ1-42 treated model group. Primary outcome: Neuronal apoptosis and PPARγ phosphorylation (p=<0.05).

Q: What does this research mean for the field?

Ginsenoside Rg1 reduces Aβ1-42-induced neuronal apoptosis and inhibits PPARγ phosphorylation by downregulating CDK5 expression. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Amy T. Wang; Steven A. Smith

doi:10.7326/0003-4819-153-12-201012210-02011

December 1, 2010Annals of Internal Medicine

In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and mortality compared with pioglitazone

View at Publisher

Ask AI

Bookmark

Share

Why the study?

Rosiglitazone and pioglitazone, both TZDs and PPARγ agonists, have differing safety profiles with concerns about rosiglitazone increasing risks of stroke, heart failure, and mortality in elderly patients.

PICO

P

Population

150 2-day-old Sprague Dawley rats (50% female) were used to isolate primary hippocampal neurons for an in vitro Alzheimer's disease model.

I

Intervention / Comparator

Ginsenoside Rg1 vs Aβ1-42 treated model group (60 µM)

O

Primary Outcome

Neuronal apoptosis and PPARγ phosphorylation, p=<0.05

Main Result

p-value: p=<0.05

Limitations

No experiments such as chromatin immunoprecipitation RT-qPCR were performed to confirm whether CDK5 directly regulates PPARγ.
No in vivo studies were conducted and only in vitro experiments were performed.
No positive-control drug was used in the study.
CDK5 overexpression experiments were not performed due to limitations on time and funding.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2010) studied Alzheimer's disease (in vitro model) (n=150). Ginsenoside Rg1 vs. Aβ1-42 treated model group was evaluated on Neuronal apoptosis and PPARγ phosphorylation (p=<0.05).

synapsesocial.com/papers/6ac469208a4dee4d20203ffe https://doi.org/10.7326/0003-4819-153-12-201012210-02011

View at Publisher

Ask AI

Bookmark

Share

In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and mortality compared with pioglitazone

PICO

Main Result

Limitations

Ask about this paper

Abstract

Discussion

Cite This Study

In older patients, rosiglitazone was associated with increased risk for stroke, heart failure, and mortality compared with pioglitazone

PICO

Main Result

Limitations

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading